Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Taberminogene vadenovec

Drug Profile

Taberminogene vadenovec

Alternative Names: EG004; Trinam; Vascular endothelial growth factor D gene therapy - Ark Therapeutics

Latest Information Update: 16 Mar 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ark Therapeutics
  • Class Gene therapies; Vascular disorder therapies
  • Mechanism of Action Gene transference; Vascular endothelial growth factor D expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Vascular restenosis
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Vascular restenosis

Most Recent Events

  • 09 Sep 2010 Taberminogene vadenovec is available for licensing as of 09 Sep 2010. http://www.arktherapeutics.com
  • 14 May 2010 Phase-II/III clinical trials in Vascular restenosis in USA (IM)
  • 05 May 2010 Taberminogene vadenovec is available for licensing worldwide (http://www.arktherapeutics.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top